|Bid||8.80 x 1000|
|Ask||9.00 x 1300|
|Day's range||8.15 - 8.88|
|52-week range||7.08 - 40.91|
|Beta (5Y monthly)||2.18|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Aug 1996|
|1y target est||12.00|
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
VIENNA, Va., July 07, 2021--CEL-SCI Corporation issues letter to shareholders.
Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study.